Sign In
Buy MRNS
$0.550
+0 (+0%)
At Close: May 09, 2025
Sep 30, 2020 (The Expresswire) --
Global Paediatric Neuropsychiatric Disorders Treatment Market Report tracks the major market events including product...
Enhanced Healthcare Partners Announces Investment in NeuroPsychiatric Hospitals
12:00am, Wednesday, 30'th Sep 2020
Enhanced Healthcare Partners (“EHP”), a leading healthcare-focused private equity firm specializing in middle-market healthcare services businesses, i
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:04am, Wednesday, 12'th Aug 2020
Marinus Pharmaceuticals announced the grant of inducement awards to seven new employees.
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12:00am, Wednesday, 12'th Aug 2020
Marinus Pharmaceuticals announced the grant of inducement awards to seven new employees.
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
11:30am, Thursday, 06'th Aug 2020
Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020.
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
12:00am, Thursday, 06'th Aug 2020
Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020.
Have Insiders Been Buying Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Shares?
04:13pm, Tuesday, 04'th Aug 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Why Marinus Pharmaceuticals Is Trading Higher Today
02:52pm, Thursday, 30'th Jul 2020
Marinus Pharmaceuticals (NASDAQ: MRNS) shares are trading higher on Thursday after the company announced it has received FDA rare pediatric disease designation for Ganaxolone for the treatment of CDKL
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and D
Marinus Pharmaceuticals Appoints Charles Austin to Board of Directors
08:00pm, Wednesday, 29'th Jul 2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) has appointed former Johnson & Johnson Corporate VP Charles "Chuck" Austin to its Board of Directors.
104,981 Shares in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) Purchased by Parallel Advisors LLC
06:12am, Monday, 20'th Jul 2020
Parallel Advisors LLC purchased a new stake in shares of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) during the second quarter, HoldingsChannel.com reports. The firm purchased 104,981 shares of the biop
Were Hedge Funds Right About Piling Into Marinus Pharmaceuticals Inc (MRNS)?
01:19am, Thursday, 09'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Nuveen Asset Management LLC Increases Stock Holdings in Marinus Pharmaceuticals Inc (NASDAQ:MRNS)
05:14am, Monday, 06'th Jul 2020
Nuveen Asset Management LLC raised its stake in Marinus Pharmaceuticals Inc (NASDAQ:MRNS) by 56.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commissi
Oppenheimer Weighs in on Marinus Pharmaceuticals Inc’s Q3 2020 Earnings (NASDAQ:MRNS)
02:14am, Saturday, 04'th Jul 2020
Marinus Pharmaceuticals Inc (NASDAQ:MRNS) – Stock analysts at Oppenheimer raised their Q3 2020 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a report issued on Tuesday, June 30th
HC Wainwright Reaffirms “Buy” Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)
06:32am, Friday, 03'rd Jul 2020
HC Wainwright reaffirmed their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Tuesday, AnalystRatings.com reports. HC Wainwright currently has a $9.00 price target
